MRI (magnetic resonance imaging) imaging agent gains NCI (US National Cancer Institute) support:
This article was originally published in Clinica
Executive Summary
Targesome has received support from the US National Cancer Institute (NCI) to further its development of an MRI-based molecular imaging agent that can help detect cancer and metastatic disease. The Palo Alto, California company is investigating the use of its proprietary nanoparticles that target new blood vessel formation, a process essential for tumour growth and metastases. The technique involves the use of a human monoclonal antibody which is attached to Targesome's injectable nanoparticles labelled with gadolinium ions and which binds to a specific endothelial marker.